Phase:III, II
Principal Investigator(s):Quarraisha Abdool Karim, PhD
Objective:To assess the effectiveness of an implementation model which integrates tenofovir gel provision into existing family planning services.
Prevention Option(s):Microbicides
Study Design:Controlled, Placebo
Arms and Assigned Interventions
Description1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of QI methodology to promote reliable service delivery
Mode of DeliveryGel
Official Code: NCT01691768
Trial Sponsors: CAPRISA, CONRAD, FHI 360, Gilead Sciences, Institute for Health Care Improvement
Start Date
End Date
October 31, 2012
December 31, 2015
Age range: 18 Years ↔ any
Population:Cisgender Women